The U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squib new type 2 diabetes treatme…
Farxiga
FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has decided (13-1) in favor of Bristol-Myers Squ…
AstraZeneca and Bristol-Myers Squibb Resubmit New Type 2 Diabetes Treatment for FDA Approval
AstraZeneca and Bristol-Myers Squibb Company resubmitted a New Drug Application (NDA) to the U.S. FDA for the investigat…
Experimental Diabetes Drug Shows Improved Glycemic Control
A new study evaluating the efficacy and safety of adding dapagliflozin therapy to the treatment of type 2 diabetes patie…
FDA Requests Additional Data on Type 2 Diabetes Drug Dapagliflozin
The FDA has issued a complete response letter regarding the New Drug Application (NDA) for investigational compound dapa…
FDA Advisory Committee Votes Against Type 2 Diabetes Drug Dapagliflozin
The U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting reached a de…
New Investigational Drug Improved HbA1c in Adults with Type 2 Diabetes
Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double blind Phase 3 clinical study, …
Bristol-Myers Squibbs’ Dapagliflozin Demonstrated Improved Glycemic Control in Adults with Type 2 Diabetes
Bristol-Myers announced that findings from a 24-week Phase 3 clinical study, published online in the latest issue of Dia…
Sirona Biochem Corp. Says New Results Show SGLT2 Sugar Blockers Could Help Fight Diabetes
In a press release dated November 17, Sirona Biochem Corp. announced that results of their latest clinical trials showed…
